analyzed the efficacy and safety of SGLT2 inhibitors in a cohort of 12 patients with partial lipodystrophy (4 with variants in LMNA, 1 in PPARG, 1 in PCYT1A, and 6 with unknown mutations). The gene discussed is PPARG; the disease is partial lipodystrophy.